Published On: Mon, Sep 19th, 2016

Ultragenyx Pharmaceutical Inc. (RARE) Given a $109.00 Price Target at Jefferies Group

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received a $109.00 price target from Jefferies Group in a report released on Sunday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price target would suggest a potential upside of 42.33% from the company’s current price.
Several other equities research analysts have also recently issued reports on RARE. Leerink Swann reaffirmed a “buy” rating and issued a $85.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. JMP Securities reaffirmed a “buy” rating and issued a $84.00 target price (up from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 8th. Finally, JPMorgan Chase & Co. set a $110.00 target price on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Monday, August 8th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $97.32.
Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.70% on Friday, reaching $76.58. The company’s stock had a trading volume of 1,159,582 shares. The firm has a 50-day moving average of $65.61 and a 200-day moving average of $62.65. The company’s market capitalization is $3.02 billion. Ultragenyx Pharmaceutical has a one year low of $46.52 and a one year high of $133.40.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/ultragenyx-pharmaceutical-inc-rare-given-a-109-00-price-target-at-jefferies-group-2.html

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.02. During the same period in the previous year, the company earned ($0.83) earnings per share. Analysts predict that Ultragenyx Pharmaceutical will post ($5.93) EPS for the current year.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the completion of the transaction, the chief executive officer now owns 513,597 shares in the company, valued at $26,116,407.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sunil Agarwal sold 649 shares of the business’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total value of $34,189.32. The disclosure for this sale can be found here. Company insiders own 10.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Ultragenyx Pharmaceutical by 79.9% in the first quarter. Wellington Management Group LLP now owns 4,132,430 shares of the biopharmaceutical company’s stock worth $261,625,000 after buying an additional 1,835,196 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 4.9% in the second quarter. Vanguard Group Inc. now owns 2,589,718 shares of the biopharmaceutical company’s stock worth $126,664,000 after buying an additional 120,999 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Ultragenyx Pharmaceutical by 14.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,774,736 shares of the biopharmaceutical company’s stock worth $199,090,000 after buying an additional 219,746 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Ultragenyx Pharmaceutical by 1.6% in the first quarter. BlackRock Fund Advisors now owns 1,442,851 shares of the biopharmaceutical company’s stock worth $91,347,000 after buying an additional 23,389 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock worth $81,315,000 after buying an additional 300,901 shares during the last quarter. Institutional investors and hedge funds own 93.06% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>